miR‐34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo‐sensitivity and malignancy

Identification of factors to detect chemotherapy‐resistant tumours at diagnosis is a first priority for risk‐adapted therapy in the oncology of children and young adults, where more individualized, effective, and less toxic treatments are highly desirable. In this study, we analysed the miRNAs discriminating Ewing's sarcoma (EWS) patients with different clinical outcomes in order to identify new indicators of prognosis. miRNA expression was investigated in 49 primary EWSs by using the Agilent human miRNA microarray v.2 and/or qRT‐PCR. Statistical power of the samples studied for miRNA expression was verified, indicating adequate sample size. Microarray analysis defined a signature of five miRNAs (miR‐34a, miR‐23a, miR‐92a, miR‐490‐3p, and miR‐130b) as an independent predictor of risk for disease progression and survival. Validation analysis in the extended sample set indicated that both miR‐34a and miR‐490‐3p achieved sufficient statistical power to predict prognosis. Results were particularly robust for miR‐34a, which appeared associated with either event‐free or overall survival and emerged as a significant predictor also after multivariate analysis. Patients with the highest expression of miR‐34a did not experience adverse events in 5 years; in contrast, patients with the lowest expression recurred within 2 years. High expression of miR34a can be detected also in paraffin‐embedded tissues by in situ hybridization, thus contributing to an easy routine evaluation of this miRNA. Functional analysis of miR‐34a in EWS cell lines indicated that when miR‐34a expression was enforced, cells were less proliferative, less malignant, and sensitized to doxorubicin and vincristine. Expression of miR‐34a could be increased in p53wt cells by treatment with nutlin‐3a. Accordingly, nutlin‐3a synergizes with doxorubicin. Overall, our data indicate that miR‐34a expression is a strong predictor of outcome in EWS. Restoration of miR‐34a activity may be useful to decrease malignancy and increase tumour sensitivity to current drugs, so sparing excessive long‐term toxicity to EWS patients. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  S. Ferrari,et al.  Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  B. Nielsen,et al.  Robust one-day in situ hybridization protocol for detection of microRNAs in paraffin samples using LNA probes. , 2010, Methods.

[3]  M. Brown,et al.  Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma , 2010, Clinical Cancer Research.

[4]  Y. Iwamoto,et al.  Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors. , 2010, Cancer letters.

[5]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[6]  U. Dirksen,et al.  Approaching Ewing sarcoma. , 2010, Future oncology.

[7]  Aaron R Cooper,et al.  Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma , 2010, Clinical Cancer Research.

[8]  Nicolò Riggi,et al.  EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. , 2010, Genes & development.

[9]  M. Fabbri.  miRNAs as molecular biomarkers of cancer , 2010, Expert review of molecular diagnostics.

[10]  Massimo Negrini,et al.  Micromarkers: miRNAs in cancer diagnosis and prognosis , 2010, Expert review of molecular diagnostics.

[11]  H. Hermeking.  The miR-34 family in cancer and apoptosis , 2010, Cell Death and Differentiation.

[12]  O. Myklebost,et al.  Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort , 2010, Genes, chromosomes & cancer.

[13]  Lijun Liu,et al.  Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. , 2009, Biochemical and biophysical research communications.

[14]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[15]  H. Hermeking.  An interview with Dr. Heiko Hermeking on his highly cited paper published in Cell Cycle , 2009 .

[16]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[17]  Nicolò Riggi,et al.  Identification of cancer stem cells in Ewing's sarcoma. , 2009, Cancer research.

[18]  Yasunori Fujita,et al.  Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.

[19]  Dirk Winkler,et al.  miR-34a as part of the resistance network in chronic lymphocytic leukemia. , 2008, Blood.

[20]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[21]  Izumi Horikawa,et al.  Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. , 2008, Cancer research.

[22]  Heidi J. Peltier,et al.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. , 2008, RNA.

[23]  U. Dirksen,et al.  Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. , 2008, European journal of cancer.

[24]  Lin He,et al.  The guardian's little helper: microRNAs in the p53 tumor suppressor network. , 2007, Cancer research.

[25]  H. Hermeking.  p53 enters the microRNA world. , 2007, Cancer cell.

[26]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[27]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[28]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[29]  Jeremy J. W. Chen,et al.  Unique MicroRNA signature and clinical outcome of cancers. , 2007, DNA and cell biology.

[30]  O. Delattre,et al.  Mesenchymal stem cell features of Ewing tumors. , 2007, Cancer cell.

[31]  S. Ferrari,et al.  Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998 , 2006, Acta oncologica.

[32]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[34]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[35]  P. Meltzer,et al.  Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.

[36]  A. Llombart‐Bosch,et al.  Molecular Analysis of the 9p21 Locus and p53 Genes in Ewing Family Tumors , 2001, Laboratory Investigation.

[37]  W D Plummer,et al.  Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.

[38]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[39]  T. Triche,et al.  The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. , 1994, The New England journal of medicine.

[40]  D. McCance.  Pathological Society of Great Britain and Ireland , 1984 .

[41]  J. Haier,et al.  MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. , 2010, European journal of cancer.

[42]  H. Hermeking.  MiR-34a and p53. , 2009, Cell Cycle.